Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
Public ClinicalTrials.gov record NCT02582684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV. DTG is a type of HIV medicine called an integrase inhibitor; 3TC is a type of HIV medicine called a reverse transcriptase inhibitor. DTG works by blocking integrase and 3TC works by blocking reverse transcriptase, two HIV proteins (enzymes). This prevents HIV from multiplying and lowers the viral load (amount of HIV in the blood). Both DTG and 3TC are currently part of Food and Drug Administration (FDA) recommended regimens along with a third active drug. Since some HIV medicines have side effects and are costly, there is interest in whether HIV can be successfully controlled with fewer than three HIV drugs.
Study identification
- NCT ID
- NCT02582684
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2015
- Primary completion
- Feb 27, 2017
- Completion
- Sep 25, 2017
- Last update posted
- May 8, 2018
2015 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California CRS (1201) | Los Angeles | California | 90033 | — |
| UCLA CARE Center CRS (601) | Los Angeles | California | 90095 | — |
| Ucsd, Avrc Crs (701) | San Diego | California | 92103 | — |
| Harbor-UCLA Med. Ctr. CRS (603) | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Univ. of Miami AIDS CRS (901) | Miami | Florida | 33136 | — |
| The Ponce de Leon Center CRS (5802) | Atlanta | Georgia | 30308 | — |
| Northwestern University CRS (2701) | Chicago | Illinois | 60611 | — |
| Rush Univ. Med. Ctr. ACTG CRS (2702) | Chicago | Illinois | 60612 | — |
| Massachusetts General Hospital ACTG CRS (101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hosp. ACTG CRS (107) | Boston | Massachusetts | 02115 | — |
| Washington University CRS (2101) | St Louis | Missouri | 63110 | — |
| Cornell CRS (7804) | New York | New York | 10011 | — |
| Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803) | New York | New York | 10011 | — |
| Columbia Physicians and Surgeons CRS (30329) | New York | New York | 10032 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) | Rochester | New York | 14642 | — |
| 3201 Chapel Hill CRS | Chapel Hill | North Carolina | 27516 | — |
| Greensboro CRS (3203) | Greensboro | North Carolina | 27401 | — |
| Univ. of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| The Ohio State Univ. AIDS CRS (2301) | Columbus | Ohio | 43210 | — |
| Hosp. of the Univ. of Pennsylvania CRS (6201) | Philadelphia | Pennsylvania | 19104 | — |
| The Miriam Hospital ACTG CRS (2951) | Providence | Rhode Island | 02906 | — |
| Vanderbilt Therapeutics CRS (3652) | Nashville | Tennessee | 37204 | — |
| 31443 Trinity Health and Wellness Center CRS | Dallas | Texas | 75208 | — |
| Houston AIDS Research Team CRS (31473) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02582684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2018 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02582684 live on ClinicalTrials.gov.